同时存在的ATTR Amyloidosis和冠状动脉疾病:一种危险的组合
Arnaud Planchat1, Damien Guijarro1, Yazan Musayeb1
1Structural Heart Unit, Cardiology Division, Department of Medicine Geneva University Hospitals Geneva Switzerland.
Clinical case reports
|October 13, 2025
概括
心脏粉症复杂化冠状动脉疾病,皮肤冠状动脉干预 (PCI) 后的结果恶化. 多模式成像对于诊断这种具有挑战性的疾病至关重要.
科学领域:
- 心脏病学 心脏病学
- 心血管成像 - 心血管成像
- 氨基粉症研究研究
背景情况:
- 心脏粉症和冠状动脉疾病 (CAD) 是一个复杂的临床挑战.
- 粉样蛋白沉积有助于动脉样硬化和室内微血管功能障碍.
- 粉症中的限制性心肌病症加剧了皮肤穿透冠状动脉干预 (PCI) 期间的并发症.
研究的目的:
- 为了突出同时存在的心脏粉症和CAD的诊断复杂性.
- 强调粉样粉症对PCI结果的影响.
- 在怀疑心脏粉样化症时倡导采用多式成像策略.
主要方法:
- 对涉及心脏粉症和CAD的临床情景的审查.
- 分析粉样蛋白沉积和血管疾病之间的病理生理相互作用.
- 讨论用于诊断心脏粉样化症的成像方法.
主要成果:
- 粉样纤维素沉积促进动脉样硬化和微血管疾病.
- 心脏粉样粉症显著增加了与PCI相关的风险.
- 多式成像技术有助于诊断心脏粉症.
结论:
- 心脏 Amyloidosis 和 CAD 的联合存在带来了重大的临床和程序性挑战.
- 粉样症相关的心力衰竭复杂化了PCI,需要仔细的患者管理.
- 一种全面的多式成像方法对于准确的诊断和有效的治疗计划至关重要.
更多相关视频
相关概念视频
Coronary Artery Disease I: Introduction
878
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
878
Coronary Artery Disease II: Pathophysiology
367
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
367
Coronary Artery Disease IV: Preventive Measures
589
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
589
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
354
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
354
Coronary Artery Disease III: Clinical Manifestations
325
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
325
Atherosclerosis III: Management
319
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
319


